We will develop a novel approach to detecting transgene activity in tumors based on proton MRI of enzyme activated reporter molecules. Specifically, we will synthesize, evaluate, optimize, and apply novel agents to detect (3-galactosidase activity generated by the lacZ gene. Gene therapy holds great promise for treatment of cancer. However, major problems involve assessing delivery to target tissue, the uniformity (versus heterogeneity) of bio distribution and determining whether the genes are expressed. We propose a novel approach for evaluating gene expression using MRI. This research draws on foundations in optical detection of reporter genes, specifically P- galactosidase from the lacZ gene. Recently, 3,4-cyclohexenoesculetin-p-galactopyranoside, marketed commercially as S-Gal(tm), has been shown to generate an intense black color as a precipitate upon activation by p-gal in the presence of Fe3+ ions. This prompted us to consider the paramagnetic properties of the precipitate as a potential 1H MRI contrast agent. Preliminary studies have demonstrated feasibility and we now wish to translate and develop the concept to tumor cells for detection in vivo.
Specific aim 1 will explore the utility of S-gal, with investigations to optimize and validate the technique. MRI parameters will be varied to maximize contrast with appropriate spatial and temporal resolution. Agent administration will be evaluated to maximize contrast and minimize toxicity.
Specific aim 2 will focus on translation to tumors in living mice. MRI will be validated by comparison with optical methods in vivo and traditional methods such as histology and RT-PCR.
Specific aim 3 focuses on the synthesis and development of alternate optimized substrates. We believe this approach can both become a valuable tool for detecting p-gal activity in vivo and serve as a proof of principle for a novel platform technology adaptable to other reporter genes and endogenous enzymes such as proteases. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA120774-01A1
Application #
7211047
Study Section
Special Emphasis Panel (ZRG1-SBIB-J (51))
Program Officer
Menkens, Anne E
Project Start
2007-06-01
Project End
2009-05-31
Budget Start
2007-06-01
Budget End
2008-05-31
Support Year
1
Fiscal Year
2007
Total Cost
$157,000
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
LoRicco, Josephine G; Xu, Changmingzi Sherry; Neidleman, Jason et al. (2016) Gallic Acid Is an Antagonist of Semen Amyloid Fibrils That Enhance HIV-1 Infection. J Biol Chem 291:14045-55
Gulaka, Praveen K; Yu, Jian-Xin; Liu, Li et al. (2013) Novel S-Gal(®) analogs as (1)H MRI reporters for in vivo detection of ?-galactosidase. Magn Reson Imaging 31:1006-11
Yu, Jian-Xin; Hallac, Rami R; Chiguru, Srinivas et al. (2013) New frontiers and developing applications in 19F NMR. Prog Nucl Magn Reson Spectrosc 70:25-49
Yu, Jian-Xin; Kodibagkar, Vikram D; Hallac, Rami R et al. (2012) Dual 19F/1H MR gene reporter molecules for in vivo detection of ýý-galactosidase. Bioconjug Chem 23:596-603
Yu, Jian-Xin; Gulaka, Praveen K; Liu, Li et al. (2012) Novel Fe(3+)-Based (1)H MRI ?-Galactosidase Reporter Molecules** Chempluschem 77:370-378
Liu, Li; Mason, Ralph P (2010) Imaging beta-galactosidase activity in human tumor xenografts and transgenic mice using a chemiluminescent substrate. PLoS One 5:e12024
Cui, Weina; Liu, Li; Kodibagkar, Vikram D et al. (2010) S-Gal, a novel 1H MRI reporter for beta-galactosidase. Magn Reson Med 64:65-71